SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the "Board"), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service. "Julianne i ...

Core Viewpoint - Novo Nordisk is anticipated to exceed revenue and earnings estimates for Q1 2025, with projected revenues of $11.33 billion and earnings of 91 cents per share [1] Financial Estimates - The Zacks Consensus Estimate for Novo Nordisk's Q1 2025 earnings per share (EPS) has decreased from $0.92 to $0.91 over the past 30 days, while the 2025 EPS forecast has dropped from $3.88 to $3.81 [2] - The current EPS estimates for Q1 and Q2 2025 are both at $0.91, while the full-year estimates for 2025 and 2026 are $3.81 and $4.66, respectively [2] Earnings Performance - Novo Nordisk has had a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 1.97% [5] - The last reported quarter showed a significant earnings surprise of 9.64% [5] Market Position and Product Performance - Revenue growth in Q1 2025 is expected to be driven by strong demand for diabetes and obesity care medicines, particularly semaglutide [9] - Wegovy is projected to be a key contributor to top-line growth due to strong prescription trends and expanded labeling in the U.S. and EU [10] - Sales of Ozempic are also expected to have increased, supported by rising demand, along with strong performance from Rybelsus and certain insulin products [11] Competitive Landscape - Novo Nordisk faces significant competition from Eli Lilly, which has seen success with its obesity and diabetes treatments, potentially impacting Novo's market share [20] - Other companies, such as Amgen and Viking Therapeutics, are also advancing in the GLP-1-based treatment space, increasing competitive pressure [21] Regulatory and Market Challenges - Medicare's decision not to cover weight-loss drugs like Wegovy may limit patient access and contribute to stock declines [22] - Broader macroeconomic factors, including potential tariffs on pharmaceuticals, pose risks to the industry [23] Strategic Developments - Novo Nordisk is making progress with its pipeline, including new candidates for diabetes and obesity, and is expanding manufacturing capacity to strengthen its market position [24][25] - Recent price cuts for obesity medications have improved patient access and are expected to drive sales growth [26] Investment Outlook - Despite recent challenges, Novo Nordisk is viewed as a long-term investment opportunity due to its strong fundamentals and growth potential in the expanding obesity market [27][28] - The company's efforts to expand product labels and improve access through price reductions are expected to support future revenue growth [28]